Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies
Cryoport (NASDAQ: CYRX) has unveiled its new Cryoport Express® Cryogenic HV3 Shipping System, designed for transporting biologics and temperature-sensitive materials. The HV3's innovative features include a rectilinear design that eliminates palletization needs, enabling transport on narrow-bodied aircraft and reducing flight rejections.
The system maintains temperatures at -150°C or lower and includes enhanced payload protection, additional space for accessories, and improved storage efficiency through stacking capabilities. Key features include integrated condition monitoring, robust wheels, and front-facing handles for better point-of-care accessibility.
The HV3 is compatible with Cryoport's Safepak® System and will be showcased at Phacilitate's Advanced Therapies Week in Dallas. The innovation aims to improve patient access to vital cell therapies in smaller cities and remote areas by increasing available shipping lanes and ensuring compliance with regional carriers.
Cryoport (NASDAQ: CYRX) ha presentato il suo nuovo sistema di spedizione criogenico Cryoport Express® HV3, progettato per trasportare materiali biologici e sensibili alla temperatura. Le caratteristiche innovative dell'HV3 includono un design rettilineo che elimina la necessità di palletizzazione, consentendo il trasporto su aerei a fusoliera stretta e riducendo i rifiuti di volo.
Il sistema mantiene temperature a -150°C o inferiori e include una protezione migliorata del carico utile, spazio aggiuntivo per gli accessori e una maggiore efficienza di stoccaggio grazie alle capacità di impilamento. Tra le caratteristiche principali ci sono monitoraggio delle condizioni integrato, ruote robuste e maniglie frontali per una migliore accessibilità nei punti di cura.
L'HV3 è compatibile con il sistema Safepak® di Cryoport e verrà presentato durante la Advanced Therapies Week di Phacilitate a Dallas. L'innovazione mira a migliorare l'accesso dei pazienti a terapie cellulari vitali in città più piccole e aree remote aumentando le rotte di spedizione disponibili e garantendo la conformità con i vettori regionali.
Cryoport (NASDAQ: CYRX) ha presentado su nuevo sistema de envío criogénico Cryoport Express® HV3, diseñado para transportar productos biológicos y materiales sensibles a la temperatura. Las características innovadoras del HV3 incluyen un diseño rectilíneo que elimina la necesidad de paletización, permitiendo el transporte en aviones de fuselaje estrecho y reduciendo los rechazos de vuelo.
El sistema mantiene temperaturas de -150°C o inferiores e incluye protección mejorada de la carga útil, espacio adicional para accesorios y una mayor eficiencia de almacenamiento a través de capacidades de apilamiento. Las características clave incluyen monitoreo de condiciones integrado, ruedas robustas y asas frontales para una mejor accesibilidad en el punto de atención.
El HV3 es compatible con el sistema Safepak® de Cryoport y se mostrará en la Advanced Therapies Week de Phacilitate en Dallas. La innovación tiene como objetivo mejorar el acceso de los pacientes a terapias celulares vitales en ciudades más pequeñas y áreas remotas al aumentar las rutas de envío disponibles y garantizar el cumplimiento con los transportistas regionales.
크라이오포트 (NASDAQ: CYRX)가 생물학적 제품 및 온도 민감 물질을 운송하기 위해 설계된 새로운 크라이오포트 익스프레스® 냉동 HV3 운송 시스템을 공개했습니다. HV3의 혁신적인 특징은 팔레트화 필요성을 제거하는 직선 디자인으로, 좁은 기체 항공기에서의 운송을 가능하게 하고 비행 거부를 줄여줍니다.
시스템은 -150°C 이하의 온도를 유지하며, 향상된 적재 보호, 액세서리를 위한 추가 공간 및 적층 기능을 통한 저장 효율성 향상을 포함합니다. 주요 특징으로는 통합 상태 모니터링, 견고한 바퀴 및 더욱 원활한 접근을 위한 전면 손잡이가 포함됩니다.
HV3는 크라이오포트의 Safepak® 시스템과 호환되며, 댈러스에서 열리는 파시리테이트의 고급 치료 주간에서 선보일 예정입니다. 이 혁신은 소규모 도시와 외딴 지역에서 환자들이 중요한 세포 치료를 이용할 수 있도록 보장하고, 이용 가능한 운송 경로를 늘리며 지역 운송업체와의 준수를 보장하는 것을 목표로 하고 있습니다.
Cryoport (NASDAQ: CYRX) a dévoilé son nouveau système d'expédition cryogénique Cryoport Express® HV3, conçu pour transporter des produits biologiques et des matériaux sensibles à la température. Les caractéristiques innovantes du HV3 incluent un design rectiligne qui élimine le besoin de palettisation, permettant le transport sur des avions à fuselage étroit et réduisant les rejets de vol.
Le système maintient des températures de -150°C ou moins et comprend une protection améliorée de la charge utile, un espace supplémentaire pour les accessoires, et une meilleure efficacité de stockage grâce à des capacités d'empilage. Les caractéristiques clés incluent un suivi des conditions intégré, des roues robustes et des poignées avant pour un meilleur accès aux soins.
Le HV3 est compatible avec le système Safepak® de Cryoport et sera présenté lors de la Advanced Therapies Week de Phacilitate à Dallas. L'innovation vise à améliorer l'accès des patients à des thérapies cellulaires vitales dans des villes plus petites et des zones éloignées en augmentant les voies d'expédition disponibles et en garantissant la conformité avec les transporteurs régionaux.
Cryoport (NASDAQ: CYRX) hat sein neues Cryoport Express® Kryogenik HV3 Versand System vorgestellt, das für den Transport von Biologika und temperaturempfindlichen Materialien konzipiert ist. Die innovativen Merkmale des HV3 umfassen ein geradliniges Design, das die Notwendigkeit der Palettierung eliminiert, sodass der Transport in schmalen Flugzeugen ermöglicht wird und Flugablehnungen verringert werden.
Das System hält Temperaturen von -150°C oder darunter und bietet verbesserten Schutz des Nutzlasts, zusätzlichen Platz für Zubehör und eine verbesserte Lager-effizienz durch Stapelmöglichkeiten. Zu den wichtigsten Merkmalen gehören integrierte Zustandsüberwachung, robuste Räder und frontale Griffe für eine bessere Zugänglichkeit an den Versorgungsstellen.
Das HV3 ist mit dem Safepak® System von Cryoport kompatibel und wird während der Advanced Therapies Week von Phacilitate in Dallas präsentiert. Die Innovation zielt darauf ab, den Patienten in kleineren Städten und abgelegenen Gebieten den Zugang zu wichtigen Zelltherapien zu erleichtern, indem die verfügbaren Versandwege erhöht und die Einhaltung der regionalen Transportdienste sichergestellt wird.
- New HV3 shipping system expands market reach by enabling transport on narrow-bodied aircraft
- Improved storage efficiency through stacking capability reduces operational costs
- Enhanced payload protection and monitoring system ensures better product integrity
- Design improvements reduce need for additional site-based resources
- None.
Insights
The launch of Cryoport's HV3 shipping system represents a significant technological advancement in biologic material transportation. The rectilinear design's compatibility with narrow-bodied aircraft addresses a important industry bottleneck by expanding available shipping lanes and reducing flight rejections. This innovation could potentially increase Cryoport's market share in the
The system's stackable design and improved storage efficiency directly target operational cost reduction, while the integrated condition monitoring system strengthens the company's value proposition in maintaining critical temperature control at -150°C. The compatibility with narrow-bodied aircraft is particularly strategic for penetrating emerging markets where wide-body aircraft access is
From a competitive standpoint, the HV3's integration with the Safepak® System creates a compelling end-to-end solution that could help Cryoport capture a larger share of the cell and gene therapy logistics market, especially as this sector experiences rapid growth with numerous therapies in clinical trials.
This product launch strategically positions Cryoport to capitalize on the expanding cell and gene therapy market, which is projected to reach
- Improved point-of-care accessibility reduces handling costs and operational complexity
- Extended temperature stability strengthens competitive advantage in long-distance transportation
- Reduced flight restrictions expand market reach into previously underserved regions
The timing of this launch aligns with increasing demand for reliable cold chain solutions in the cell therapy sector, where maintaining temperature integrity is important for treatment efficacy. The product's focus on operational efficiency and expanded geographical reach could drive revenue growth through both market expansion and increased adoption among existing clients.
The HV3's design innovations address several critical operational inefficiencies in the current cold chain logistics landscape. The elimination of palletization requirements and improved stackability could reduce storage costs by
The ability to utilize narrow-bodied aircraft is particularly impactful, as it could reduce transportation costs by
New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in
The HV3 ensures unparalleled protection and accessibility for biologics and other temperature-sensitive materials. Its unique rectilinear design eliminates the need for palletization (securing goods on a pallet for transportation) and provides the ability to transport critical life science materials on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. As a result, the HV3 increases the number of available shipping lanes, which will improve patient access and enable life-saving therapies to reach patients in underserved areas.
This newly developed shipping system offers enhanced payload protection and resilience during transport. With additional space for non-temperature sensitive accessories and documentation, the HV3 also improves storage efficiency through the ability to stack and nest the shippers, making it more cost-effective and user-friendly. Full compliance with airline requirements plus an integrated condition and location monitoring system provides full Chain of Compliance®. Engineered to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security and superior temperature control, maintaining payload integrity and extended temperature stability at -150°C or lower.
The HV3's structure also enhances mobility with its robust wheels and an integrated front-facing handle, improving accessibility at point-of-care sites. Its design also provides for scalability or higher density storage capabilities at manufacturing and clinical sites. While improving overall safety for clinicians and operators, these improvements enable more efficient handling (and storage) at point-of-care sites, contract development and manufacturing organizations (CDMO's), and other storage locations, reducing the need for additional site-based resources. The HV3 is also designed to be used with Cryoport's Safepak® System. The Safepak® System is a purpose built solution that utilizes non-metallic, soft materials to minimize the effects of vibration and shock during the transport of cell and gene therapies.
"We are committed to anticipating industry challenges and continuously evolving our solutions to meet the critical needs of our clients and the patients they serve," said Jerrell Shelton, CEO, Cryoport. "With the introduction of the Cryoport Express® Cryogenic HV3 Shipping System, we are improving patient access to vital cell therapies in smaller cities and remote areas, which will ultimately improve patient outcomes at large."
The Cryoport Express® Cryogenic HV3 Shipping System will be showcased at Phacilitate's Advanced Therapies Week at booth 141, and featured during a panel discussion on patient-centric advancements in the advanced therapies supply chain on January 22, 2025, in
"With its innovative structure, improved mobility, enhanced protection and accessibility improvements, we believe the HV3 will be well-received by companies looking for user-centric solutions to the unique and considerable logistical challenges of transporting advanced therapies globally," added Mike Dybicz, Chief Product Development Officer, Cryoport Systems. "We are passionate about providing novel solutions to meet market, user and biologic product specific transport/protection challenges and are united in our shared goal of enhancing patient access to critical, life-saving therapies."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the launch of the Cryoport Express® Cryogenic HV3 Shipping System, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-unveils-state-of-the-art-cryogenic-shipping-system-for-transporting-lifesaving-biologics-and-temperature-sensitive-therapies-302355899.html
SOURCE Cryoport, Inc.
FAQ
What are the key features of Cryoport's new HV3 shipping system (CYRX)?
How does the CYRX HV3 shipping system improve patient access to therapies?
What temperature stability does Cryoport's HV3 system maintain for biologics?
When will Cryoport (CYRX) showcase the new HV3 shipping system?
What operational benefits does the CYRX HV3 shipping system offer?
